Best practices for companion diagnostic and therapeutic development: translating between the stakeholders
Authors:
- Elyse StrattonESElyse Stratton
- Michael StocumMSMichael Stocum
- 1 September 2012
- journal article
- research article
- Published by Elsevier in New Biotechnology
- Vol. 29 (6) , 689-694
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Implementation of proteomic biomarkers: making it workEuropean Journal of Clinical Investigation, 2012
- Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicineJournal of Internal Medicine, 2011
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- The Emerging Field of Quantitative Blood Metabolomics for Biomarker Discovery in Critical IllnessesAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Predictive, personalized, preventive, participatory (P4) cancer medicineNature Reviews Clinical Oncology, 2011
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2011
- The Clinical Utility of Precision Medicine: Properly Assessing the Value of Emerging Diagnostic TestsClinical Pharmacology & Therapeutics, 2010
- Determinants of Protection among HIV‐Exposed Seronegative Persons: An OverviewThe Journal of Infectious Diseases, 2010
- Accurate and objective copy number profiling using real-time quantitative PCRMethods, 2010
- Clinical Trial Designs for Evaluating the Medical Utility of Prognostic and Predictive Biomarkers in OncologyPersonalized Medicine, 2009